Resilient Biotics, Inc.

Resilient Biotics is developing non-antibiotic, microbiome-based therapeutics to combat complex respiratory infections in production animal systems. They are developing the next generation of live biotherapeutic products using a proprietary platform that incorporates high resolution genomic analyses with in-house machine learning algorithms. Resilient’s technology identifies naturally occurring microbiome-derived strains that have immune activation and pathogen inhibition properties.

Our company develops innovative microbiome products that are impactful and beneficial for the health of the planet. Our aim is to eliminate disease, reduce antibiotic resistance, and contribute to overall understanding of how the microbiome can promote host health and well-being.

Resilient Biotics is developing breakthrough live biotherapeutics to combat complex respiratory infections.

Using proprietary discovery analytics, we identify and design novel microbiome products that prevent disease-causing pathogens from taking hold in the respiratory tract. Our approach provides a new solution to help reduce dependency on antibiotics, and slow the spread of antibiotic-resistant microorganisms.

The company is building a portfolio of novel microbiome products to address major respiratory diseases in both human and animal health. Resilient is headquartered in the USA and is venture-backed by both institutional and strategic investors.

Developer of microbiome-based therapeutics and advanced screening methods designed to offer non-antibiotic treatment for respiratory infectious diseases in animals. The company's discovery platform utilizes big data analytics to identify microbiome strains that reduce pathogen colonization and promote respiratory health, enabling the animal health industry to utilize smart antibiotic replacements.